应用输尿管镜放置双J管早期治疗输尿管阴道瘘

Objective To evaluate the clinical effect of placing double J stent using a ureteroscope in early managing ureterovaginal fistula.Methods Twenty-eight patients cases with ureterovaginal fistula from 2002 to 2008 were treated early with placing double J stent using a ureteroscope and the clinical data were reviewed.Results Twenty-two of 28 cases were treated and double J stent was placed in them by a uretero-scope and 75% (21/28)of cases were cured.Four of 21 cases were treated twice by a ureteroscope and were cured finally.7 cases with failure ureterovaginal treatment underwent ureterocystostomy and were cured.The follow-up from 6 months to 33 months (average 10.1±6.4 months)showed that all of the 28 cases had been cured and had no urinary fistula.Conclusion Placing double J stent using a ureteroscope is the first choice of operative procedure for the early treatment of ureterovaginal fistula.     

应用输尿管镜放置双J管早期治疗输尿管阴道瘘

Objective To evaluate the clinical effect of placing double J stent using a ureteroscope in early managing ureterovaginal fistula.Methods Twenty-eight patients cases with ureterovaginal fistula from 2002 to 2008 were treated early with placing double J stent using a ureteroscope and the clinical data were reviewed.Results Twenty-two of 28 cases were treated and double J stent was placed in them by a uretero-scope and 75% (21/28)of cases were cured.Four of 21 cases were treated twice by a ureteroscope and were cured finally.7 cases with failure ureterovaginal treatment underwent ureterocystostomy and were cured.The follow-up from 6 months to 33 months (average 10.1±6.4 months)showed that all of the 28 cases had been cured and had no urinary fistula.Conclusion Placing double J stent using a ureteroscope is the first choice of operative procedure for the early treatment of ureterovaginal fistula.     

慢性前列腺炎三种药物疗法的费用效果分析

目的：评价吾真宁、可乐必妥、阿奇霉素(泰力特)3种治疗慢性前列腺炎药物经济学效果。方法：对75例慢性前列腺炎病人分别应用吾真宁、可乐必妥、泰力特治疗,运用药物经济学的成本-效果分析方法进行评估。结果：无论是症状消失还是体征消失的效果,吾真宁组的成本效果比均低于可乐必妥及泰力特组。结论：吾真宁为慢性前列腺炎患者提供了一种有效、安全、经济的口服药物。     

以改良TRAP法检测人膀胱肿瘤组织中端粒酶活性表达的临床意义

目的：探讨膀胱肿瘤及癌旁组织端粒酶活性表达及临床意义。方法：以改良TRAP法测定91例膀胱癌组织标本端粒酶活性表达。结果：83例膀胱移行细胞癌组织中78例检出端粒酶活性。阳性率为94％，其对应的癌旁组织也有14％的检出率，8例膀胱乳头状瘤组织中4例检出端粒酶活性，阳性率为50％，其对应的癌旁组织检出率为12％，端粒酶活性在不同临床病理类型的膀胱肿瘤及癌旁组织中表达无显差异（P＞0．05），结论：应用非放射性的银染方法对端粒酶的活性进行检测，图像清晰，简便，安全，易于临床推广。     

联合方案治疗慢性难治性前列腺炎探讨

慢性前列腺炎是泌尿外科的一种难治性疾病，根据慢性前列腺炎的病因及生理特点设计联合治疗方案。通过前列腺穿刺直接给药，辅以射频仪治疗药物吸收，口服α１Ａ受体拮抗剂改善排尿症状的三联方法，提高慢性前列腺炎的治疗效果。     

两种开放术式治疗前列腺增生症术后并发症的比较

目的：探讨Ｍａｄｄｉｇａｎ术与传统术式治疗前列腺增生症术后并发症的比较。方法：以统计学方法比较两种术式中手术时间。出血量及术后各种并发症的发生率。结果：Ｍａｄｉｇａｎ手术组病人无论在术中还是术后并发症的发生率均低于传统开放手术组。结论：Ｍａｄｉｇａｎ术为前列腺增生症病人提供了一种安全、有效、经济的手术方法。     

应用输尿管镜放置双J管早期治疗输尿管阴道瘘

Objective To evaluate the clinical effect of placing double J stent using a ureteroscope in early managing ureterovaginal fistula.Methods Twenty-eight patients cases with ureterovaginal fistula from 2002 to 2008 were treated early with placing double J stent using a ureteroscope and the clinical data were reviewed.Results Twenty-two of 28 cases were treated and double J stent was placed in them by a uretero-scope and 75% (21/28)of cases were cured.Four of 21 cases were treated twice by a ureteroscope and were cured finally.7 cases with failure ureterovaginal treatment underwent ureterocystostomy and were cured.The follow-up from 6 months to 33 months (average 10.1±6.4 months)showed that all of the 28 cases had been cured and had no urinary fistula.Conclusion Placing double J stent using a ureteroscope is the first choice of operative procedure for the early treatment of ureterovaginal fistula.     

Madigan术与传统开放术式治疗前列腺增生症术后并发症的比较

目的：比较Ｍａｄｉｎｇａｎ术与传统术式治疗前列腺增生症术后并发症。方法：以统计学方法比较两种术式中手术时间，出血量及术后各种并发症的发生率。结果：Ｍａｄｉｇａｎ手术组病人无论在术中还是在术后并发症的发生率均低于传统开放手术组。结论：Ｍａｄｉｇａｎ术为前列腺增生症病人提供了一种安全、有效、经济的手术方法。     

Ha-ras mRNA与端粒酶在人膀胱肿瘤组织中的表达

目的　探讨人膀胱癌中Ha rasmRNA及端粒酶的表达与肿瘤临床指标的关系。方法采用原位杂交及银染端粒重复序扩增程序 (TRAP)反应的方法对 91例膀胱癌标本进行Ha rasmRNA及端粒酶活性的表达检测。结果　 91例膀胱癌标本中Ha rasmRNA与端粒酶活性检出率为 73 %与 92 % ,两者阳性率及阳性强度与肿瘤的恶性程度呈正相关 ,在不同临床分期中两者表达差异无显著性 (P >0 .0 5 )。结论　Ha ras癌基因与端粒酶是参与肿瘤的发生并影响肿瘤发展的重要因素 ,有望成为判断肿瘤恶性程度、自然病程及预后的评估指标。     

前列腺增生与前列腺癌中KLK11/TMPRSSmRNA表达比值

目的 以实时荧光定量PCR技术测定前列腺增生(BPH)与前列腺癌(PCa)组织标本KLK11/TMPRSS mRNA比值,探讨KLK11/TMPRSS比值在前列腺癌诊断的特异性意义.方法 通过实时荧光定量PCR对23例PCa、37例BPH及3例正常前列腺组织KLK11/TMPRSS的表达,比较其在PCa与BPH中组织定量的差异.结果 BPH与PCa组织KLK11/TMPRSS mRNA的定量表达值分别为2.264±0.460与5.905±0.780,差异有统计学意义(P＜0.05).结论 实时荧光RTPCR定量检测KLK11/TMPRSS mRNA为前列腺癌的诊断提供了可靠的辅助指标.